Actio Biosciences
Actio Biosciences is a clinical-stage biotechnology company developing therapeutics that target shared underlying biology in both rare and common diseases using a precision medicine strategy. They are focused on developing new therapeutics to treat rare diseases like KCNT1-related epilepsy and Charcot-Marie-Tooth disease type 2C by leveraging advances in genetics and precision medicine.
Funding Round: Series B
Funding Amount: $66M
Date: 18-Jun-2025
Investors: Regeneron Ventures, Deerfield Management, Canaan, Droia Ventures, Euclidean Capital
Markets: Biotech, Therapeutics, Genetics, Pharmaceuticals, Rare Diseases
HQ: San Diego, California, United States
Founded: 2021
Website: https://actiobiosciences.com/
LinkedIn: https://www.linkedin.com/company/actiobio
Twitter: https://x.com/actiobiosci
Crunchbase: https://www.crunchbase.com/organization/actio-biosciences
Leave a Comment
Comments
No comments yet.